Device Trial Radar · NCT05943535
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
698
Planned (sponsor's estimate)
Start
Oct 30, 2023
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- United TherapeuticsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Conditions
- Progressive Pulmonary Fibrosis
- Interstitial Lung Disease
Interventions
PlaceboDrug
Placebo administered QID
Inhaled TreprostinilDrug
Inhaled treprostinil (6 mcg/breath) administered QID
Treprostinil Ultrasonic NebulizerDevice
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Absolute FVC from Baseline to Week 52Time frame: Baseline to Week 52
Locations
165 sites in 15 countries. Site status is shown where the registry gives one.
UAB Lung Health Center
Birmingham, Alabama · Recruiting
Banner University Medical Center Phoenix Lung Institute
Phoenix, Arizona · Recruiting
Norton Thoracic Institute
Phoenix, Arizona · Recruiting
162 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.